CClinicalTrials.gg
Status unknownNCT04519281Updated Aug 19, 2020

Role of Vitamin C in Cardiac Vasoplegia After Cardiopulmonary Bypass

An observational study in to Study the Effect of Vitamin C Administration on the Amount and the Time of Weaning of Noradrenaline Given Post-operatively to Patients After CPB, sponsored by Cairo University. Status unknown at 1 site in Egypt. Open to participants aged 25 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-08-19.

Sponsored by Cairo University · Observational

The sponsor has not verified this record recently (last verified Aug 2020), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
25 Years to 85 Years
Sex
All
01

Study summary

This is a parallel group double-blind, randomized-controlled trial with 1:1 randomization ratio which will be conducted over a period of 6 months to study the effect of vitamin C administration on the amount of noradrenaline given post-operatively to patients after CPB. Two groups will be included; Group (A) patients undergoing open heart surgeries who will receive IV ascorbic acid (treatment group) and Group (B) patients undergoing open heart surgeries who will not receive ascorbic acid or will receive a placebo (control group). Each patient will be subjected to assessments of the doses of noradrenaline given from the end of surgery until weaning as well as hemodynamics in the first 2 hours and then at intervals of 6 hours up to 3 days following surgery.

Read the detailed description

Background and Rationale:

Cardiac vasoplegia is a known phenomenon after cardiopulmonary bypass (CPB) occurring in up to 44% of patients. Severe forms of such condition refractory to vasopressors are associated with poor outcomes. New agents e.g. ascorbic acid that can alter the systemic vascular resistance in cardiac vasoplegia have been suggested as an attempt to avoid or at least reduce the use of IV vasopressors and their induced systemic hypo-perfusion.

Objectives :

  • Primary objective: to study the effect of vitamin C administration on the amount of noradrenaline given post-operatively to patients after CPB
  • Secondary objectives: to study the effect of vitamin C administration on the time to weaning from noradrenaline

Study population \& Sample size :

Patients undergoing cardiac surgeries with CPB having risk factors for cardiac vasoplegia like diabetes mellitus and chronic renal failure.

50 patients will be needed in each group (treatment and control)

Study Design :

A parallel group double-blind, randomized-controlled trial, with 1:1 randomization ratio 2 groups will be included;

-Group (A) patients undergoing open heart surgeries who will receive IV ascorbic acid. -Group (B) patients undergoing open heart surgeries who will not receive ascorbic acid or will receive a placebo (Control Group).

Methods :

Each patient will be subjected to the following assessments:

-Pre-operative patient characteristics: demographic data, co-morbidities, pre-operative echo findings,... -Intra-operative details: procedures, time parameters,... the doses of noradrenaline given from the end of surgery until weaning or death and hemodynamics in the first 2 hours and then at intervals of 6 hours up to 3 days following surgery. -Postoperative data: echo parameters, patient outcome, time of discharge,...

Outcome parameter (s):

-Primary outcome: the area under the dose-time curve of noradrenaline -Secondary outcome measures: the duration of vasopressor (noradrenaline) infusion till weaning up to 3 days following surgery.

02

Conditions studied

  • to Study the Effect of Vitamin C Administration on the Amount and the Time of Weaning of Noradrenaline Given Post-operatively to Patients After CPB

Browse trials for

03

Who can participate

Ages eligible
25 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

A parallel group double-blind, randomized-controlled trial, with 1:1 randomization ratio 2 groups will be included;

  • Group (A) consists of 50 patients undergoing open heart surgeries who will receive IV ascorbic acid.
  • Group (B) consists of 50 patients undergoing open heart surgeries who will not receive ascorbic acid or will receive a placebo (Control Group).

Inclusion criteria

  • Patients undergoing cardiac surgeries with CPB having risk factors for cardiac vasoplegia like diabetes mellitus and chronic renal failure.

Exclusion criteria

Exclusion Criteria:

  • Patients who undergo surgeries without cardiopulmonary bypass (off-pump)
  • Patients undergoing surgeries for congenital cardiac disease
  • Patients performing heart transplantation and combined cardiac surgeries
  • Patients with low pre-operative left ventricular ejection fraction (LVEF)
  • Patients refusing to participate
  • Patients who receive vasopressors other than noradrenaline
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
3 Days
Patient registry
Yes

Groups and cohorts

  • Group (A)

    consists of 50 patients undergoing open heart surgeries who will receive IV ascorbic acid

    Drug: IV of vitamin C

  • Group (B)

    consists of 50 patients undergoing open heart surgeries who will not receive ascorbic acid or will receive a placebo (Control Group).

Interventions

  • DrugIV of vitamin C

    administration of high-dose of IV vitamin C perioperatively

05

What researchers measure

Primary outcomes

  1. amount of noradrenaline need

    to study the effect of vitamin C administration on the amount of noradrenaline given post-operatively to patients after CPB

    Time frame: 3 days

Secondary outcomes

  1. duration of noradrenaline need

    to study the effect of vitamin C administration on the time to weaning from noradrenaline

    Time frame: 3 days

06

Study locations

1 of 1 sites recruiting
  • Cairo University
    Cairo, 11956, Egypt
    • Noha Asem, MD · Contact · kasralainirec@gmail.com · 00201003657120
    • Soha Elmorsy, MD · Sub investigator
    • Wael Siory, MD · Sub investigator
    Recruiting
07

References and documents

Publications

  • Omar S, Zedan A, Nugent K. Cardiac vasoplegia syndrome: pathophysiology, risk factors and treatment. Am J Med Sci. 2015 Jan;349(1):80-8. doi: 10.1097/MAJ.0000000000000341. PubMed 25247756 ↗
  • Fischer GW, Levin MA. Vasoplegia during cardiac surgery: current concepts and management. Semin Thorac Cardiovasc Surg. 2010 Summer;22(2):140-4. doi: 10.1053/j.semtcvs.2010.09.007. PubMed 21092891 ↗
  • Wieruszewski PM, Nei SD, Maltais S, Schaff HV, Wittwer ED. Vitamin C for Vasoplegia After Cardiopulmonary Bypass: A Case Series. A A Pract. 2018 Aug 15;11(4):96-99. doi: 10.1213/XAA.0000000000000752. PubMed 29634537 ↗

Individual participant data

Plan to share: Undecided — Clinical outcomes are to be shared

08

Registry details

Key details

Study ID
NCT04519281
Lead sponsor
Cairo University
Responsible party
Hesham Mostafa Ahmed Alkady (Prof. A. Dr., Cairo University) — Principal investigator
First posted
Aug 19, 2020
Start date
Apr 16, 2020
Primary completion
Oct 15, 2020 (estimated)
Completion
Oct 30, 2020 (estimated)
Last update
Aug 19, 2020

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion